The Medtronic Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males With Sub-optimal Response to PDE5 Inhibitors

Trial Profile

The Medtronic Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males With Sub-optimal Response to PDE5 Inhibitors

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2015

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Erectile dysfunction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ZEN
  • Sponsors Medtronic
  • Most Recent Events

    • 28 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 28 Jan 2013 Planned end date changed from 1 May 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 25 Jul 2012 New source identified and integrated (ClinicalTrials.gov record NCT01643200).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top